• WY-14643: PPARα Workflows for Metabolic Research

  2026-09-13

  WY-14643 (Pirinixic Acid) connects PPARα activation with practical studies of lipid metabolism, endothelial inflammation, insulin sensitivity, and liver regeneration. This guide combines formulation advice, cell and mouse workflows, mechanistic controls, and troubleshooting strategies for more interpretable metabolic disorder research.

• Levofloxacin: Mechanism-to-Assay Research Guide

  2026-09-12

  Levofloxacin is a synthetic fluoroquinolone antibiotic with applications spanning bacterial DNA replication, osteoblast mineralization, and cartilage biology. This guide adds a decision-focused framework for separating antibacterial mechanism studies from mammalian cell-response assays.

• PLGA Microspheres for Controlled Cartilage Corticosteroids

  2026-09-12

  The 2026 Pharmaceutics study shows that PLGA microsphere size, surface chemistry, and drug stability jointly control corticosteroid transport and release in articular cartilage. Its bovine explant, HPLC, and ester-hydrolysis analyses provide a practical framework for designing more predictable intra-articular delivery systems for osteoarthritis research.

• KR-12: Human Antimicrobial Peptide Workflows

  2026-09-11

  KR-12 is a compact LL-37-derived tool for connecting membrane disruption with biofilm, LPS, host-response, and copper-binding assays. This workflow guide covers TFA-salt preparation, quantitative antimicrobial testing, advanced use cases, and troubleshooting for reproducible KR-12 research.

• Levofloxacin Assays: Bacterial and Bone Workflows

  2026-09-11

  Levofloxacin connects bacterial DNA replication studies with practical osteoblast and chondrocyte workflows. This guide covers assay setup, exposure design, formulation, controls, and troubleshooting for more interpretable antibacterial and bone-metabolism data.

• Partial BACE Inhibition and Synaptic Transmission

  2026-09-10

  Satir et al. found that moderate BACE inhibition reduced amyloid-β secretion without impairing synaptic transmission in cultured rat cortical neurons, whereas stronger inhibition reduced both outputs. The findings support exposure strategies that lower amyloid-β production while avoiding excessive disruption of physiological APP processing.

• IGF2BP3–FZD1/7 Axis in TNBC Resistance

  2026-09-10

  This Cancer Letters study identifies IGF2BP3 as an m6A reader that stabilizes FZD1 and FZD7 transcripts, activates β-catenin signaling, and supports stem-like properties and carboplatin resistance in triple-negative breast cancer. Its preclinical findings define a therapeutically relevant IGF2BP3–FZD1/7 axis and suggest that FZD1/7 inhibition could sensitize TNBC cancer stem-like cells to carboplatin.

• Cefodizime in AMR E. coli Research

  2026-09-09

  Cefodizime provides a practical third-generation cephalosporin antibiotic framework for susceptibility testing, AMR surveillance, and controlled bacterial cell wall inhibition. Its value is greatest when researchers pair MIC measurements with resistance profiling rather than treating broad-spectrum activity as proof of universal susceptibility.

• CFDA SE Cell Tracer Kit: Practical Guide

  2026-09-09

  The CFDA SE Cell Tracer Kit provides stable, fluorescent labeling for multi-day cell tracking, cell lineage tracing, and cell proliferation studies. It is appropriate for covalent long-term labeling but should not be selected when reversible, short-term labeling or an immediate physiological readout is required.

• Vorinostat Workflows for Epigenetic Oncology

  2026-09-08

  Build reproducible Vorinostat experiments that connect HDAC inhibition with chromatin remodeling, proliferation loss, and mitochondrial apoptosis. This workflow also shows how the AMC-Hem HO-1 activity platform can serve as a carefully bounded orthogonal assay rather than an assumed mechanism.

• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-09-07

  The reference study identifies Polo-like kinase 1 as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly. Its biochemical and cell-extract experiments show that Plk1 phosphorylates p31comet at S102, reducing cooperation with TRIP13 and providing a mechanism to prevent premature checkpoint silencing.

• Ampicillin Sodium in Protein and Cell Assays

  2026-09-07

  Ampicillin sodium is more than a selection antibiotic: it is a useful experimental boundary condition in antibacterial assays and recombinant protein workflows. This article connects transpeptidase inhibition with the annexin V purification strategy reported in a foundational biophysical study.

• CGP 55845 hydrochloride for Synaptic Assays

  2026-09-05

  Use CGP 55845 hydrochloride as a selective pharmacological switch for separating GABAB-dependent signaling from astrocytic GAT-3 mechanisms in controlled in vitro experiments. Its strongest value is comparative: it links receptor antagonism, neurotransmitter release modulation, and dentate gyrus synaptic physiology without implying that it directly inhibits GAT-3.

• Linezolid: An Assay-First Guide to Resistance Biology

  2026-09-05

  Linezolid is an oxazolidinone antimicrobial whose ribosome-directed activity makes it a valuable reference compound for resistant Gram-positive pathogen research. This guide builds an evidence ladder from biochemical mechanism to whole-cell phenotypes and contrasts it with MmpL3-focused tuberculosis discovery.

• Cefazedone (Refosporen): Applied Research Workflows

  2026-09-04

  Cefazedone (Refosporen) supports practical susceptibility testing, β-lactamase-focused experiments, and translational pharmacokinetic workflows. This guide connects broth dilution design with a validated UFLC–MS/MS method for measuring cefazedone alongside etimicin in plasma.

8141 records 5/543 page Previous Next 12345 下5页 Last page